

Iain Campuzano, Keith Richardson, Therese McKenna, Alistair Wallace and James Langridge
Waters Corporation, Manchester, United Kingdom

Overview


This application note describes the use of a Bayesian probability based *de novo* sequencing algorithm automatically applied to an entire LC/MS/MS dataset. The resultant sequences are compared to the results obtained from a databank search using the same dataset.

Introduction

Large numbers of proteins from sequenced organisms can be rapidly identified from single samples in an automated manner by LC/MS/MS analysis of the tryptic digests followed by databank searching. The enhanced sensitivity, resolution and mass measurement accuracy in data produced by the Waters® Micromass® Q-ToF™ mass spectrometer considerably aids the process of inferring *de novo* amino acid sequence.

The Maximum Entropy based MassSeq™ (Proteinlynx™ Global SERVER 2.0) *de novo* sequencing algorithm performs the following after raw spectra have been processed to remove isotope and charge multiplicity.

- A terminated Markov Chain Monte Carlo algorithm simulates the exploration of huge numbers of possible sequences by taking trial sequences and altering them in a pseudo-random manner to generate new trial sequences.
- The fragmentation process is modelled using Markov Chains. This allows the sum over all the possible fragmentation patterns generated from the trial sequences to be calculated in linear time.
- The probability that each trial sequence accounts for the spectrum is calculated using Bayes' theorem.
- During the exploration, trial sequences are accepted or rejected according to this probability.



The Waters Micromass Q-ToF Mass Spectrometer

Experimental

Data acquisition

All data were acquired using a Waters® Capillary HPLC (CapLC®) system and a Q-ToF Ultima™ API, hybrid quadrupole orthogonal acceleration time-of-flight mass spectrometer (www.waters.com) fitted with a NanoLockSpray™ source. Data Directed Analysis™ (DDA™) was carried out on 100 fmol of Yeast Enolase tryptic digest. Ions were selected for MS/MS analysis based on their intensity and charge state. Collision energies were chosen automatically based on the m/z and charge-state of the selected precursor ions. All data were acquired with an internal reference ion in order to provide mass measurement accuracies of less than 10 ppm in both the MS and MS/MS mode of acquisition.

Data processing

ProteinLynx Global SERVER 2.0 was used to define a 'Workflow' template, comprising of a post-acquisition processing routine required to reduce the raw continuum MS/MS data set to a databank-searchable form, the databank to be searched and the associated query parameters (Figure 1).

A filter was applied to the dataset to discard those spectra containing insufficient information to represent a peptide. The remaining MS/MS spectra associated with each precursor ion were combined, transposed to a single charge state and reduced to a list of accurately mass measured peaks, using the MaxEnt™ 3 algorithm. Precursor and product ions were automatically lockmass corrected against Glu-fibrinopeptide B and erythromycin respectively. All data was converted to an XML format, and searched against the SwissProt v. 39 (86,865 entries, FASTA format) databank. An additional 'Workflow' was created, in which all spectra were *de novo* sequenced, with the results compared to the standard databank search. The 'Workflow' was automatically initiated upon completion of the LC/MS/MS acquisition, and the results displayed in an integrated Java interface (ProteinLynx browser).




Figure 1. Template-driven data processing. Data processing parameters were set up in the Data Preparation tool. Databank searching and *de novo* sequencing parameters were specified in separate Workflow templates.

Results

From 100 fmols of a Yeast Enolase tryptic digest, 59.6% sequence coverage was obtained from 25 unique peptides, identified by searching against SwissProt v. 39. The RMS error of all precursor ions used for the identification of Yeast Enolase was 8.01ppm. Table 1 shows a selection of peptides from the databank search (column 4) and the subsequent independent *de novo* sequencing (column 5) of the same peptides.

Two peptides *de novo* sequenced from the Yeast Enolase digest have been represented in Figure 2. Both peptides are doubly charged at m/z 392.22 and 580.31.



Figure 2a




Figure 2b

Figure 2. Full *de novo* sequence coverage of doubly charged peptides (a) 392.22 m/z and (b) 508.31 m/z from the LC/MS/MS experiment carried out on 100 fmol of injected Yeast Enolase. Also shown for each spectra are theoretical fragment masses for yⁿ, b, a and z ions, associated mass errors (Da) and MassSeq confidence level.

M/z	Charge state	Peptide mass	Database search sequence	De novo sequence
363.672	2	725.334	(R)SVYDSR(G)	SVYDSR
708.862	2	1415.714	(R)GNPTVEVELTEK(G)	GNPTVEVELTEK
362.228	2	722.444	(K)GVLAHV(K)(N)	GVLAHV
643.851	2	1285.703	(K)NVNDVIAPAFV(K)(A)	NVNDVIAPAFV
330.190	2	658.365	(K)ANIDVK(D)	ANIDVK
789.905	2	1577.794	(K)AVDDFLISLDGTANK(S)	AVDDFLISLDGTANK
367.212	2	732.417	(K)NVPLYK(H)	NVPLYK
392.219	2	782.429	(K)HLADLSK(S)	HLADLSK
404.220	2	806.429	(K)TFEAALR(I)	TFEAAL
580.302	2	1158.603	(R)IGSEVYHN(L)(S)	IGSEVYHN(L)
644.854	2	1287.703	(K)YVNDIGTLSESIK(A)	YVNDIGTLSESIK
400.692	2	799.375	(K)YDLDFK(N)	YDLDFK
771.369	2	1540.722	-	(V)PSGASTGVHEALEMR
523.763	2	1045.519	-	(I)IGSEVYHN(L)(K)
394.718	2	787.426	-	(F)MIAPTGA(K)
538.296	2	1074.592	-	(N)QIGTLSESIK

Table 1. Comparison between databank search and *de novo* sequencing. Column 4 shows a selection of peptide sequences identified by submitting data obtained by DDA to the SwissProt database. Column 5 shows the sequences obtained by *de novo* sequencing by MassSeq. Green - correctly assigned residues, Red - Incorrectly assigned, Yellow - I/L indistinguishable in low energy CID.

Upon *de novo* sequencing, the obtained sequence for ions m/z 392.22 and 580.31 were HLADLSK and LGSEVYHN(L)K respectively, which are consistent with the databank search results (Table 1). The four selected peptides of m/z 771.369, 523.763, 394.718 and 538.296 represent non-specific tryptic cleavages which were not identified by the standard databank search.

Conclusion

- The *de novo* sequencing algorithm generates high quality contiguous sequence information for long and short peptides, confirmed by the databank searching results.
- This approach can be used to identify those spectra unmatched by a databank search, due to non-tryptic cleavages or post-translational modification of the protein, thus increasing sequence coverage.
- The full automation of the *de novo* sequencing algorithm has been shown.
- The use of a NanoLockSpray source enables the mass accuracy obtained on the MS/MS fragments to be significantly enhanced (RMS error <10ppm).

Sales Offices:

AUSTRIA AND EXPORT (CENTRAL EUROPE, CIS, MIDDLE EAST,
INDIA AND INDIA SUBCONTINENT)
43 1 8771807

AUSTRALIA 61 2 9933 1777

BELGIUM AND LUXEMBOURG
32 02 726 1000

BRAZIL 55 11 5543 7788

CANADA 800 252 4752 X2205

CIS 7 095 931 9193

CZECH REPUBLIC 420 2 617 11384

DENMARK 45 46 59 8080

FINLAND 358 09 506 4140

FRANCE 33 1 3048 7200

GERMANY 49 6196 40 06 00

HONG KONG 852 29 64 1800

HUNGARY 36 1 350 5086

INDIA 91 80 837 1900

IRELAND 353 1 4481500

ITALY 39 02 274211

JAPAN 81 3 3471 7191

KOREA 82 2 3284 1300

MEXICO 52 55 5524 7636

THE NETHERLANDS 31 76 508 7200

NORWAY 47 6 384 6050

PEOPLES REPUBLIC OF CHINA
86 10 8451 8918

POLAND 48 22 833 4400

PUERTO RICO 1 787 747 8445

SINGAPORE 65 6278 7997

SPAIN 34 93 600 9300

SWEDEN 46 555 11 500

SWITZERLAND 41 62 889 2030

TAIWAN 886 2 2543 1898

UK 44 208 238 6100

U.S.A. AND ALL OTHER COUNTRIES:

WATERS CORPORATION
34 Maple St.
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990

WATERS CORPORATION
34 Maple St.
Milford, MA 01757 U.S.A.
T: 508 478 2000
F: 508 872 1990
www.waters.com/micromass

Produced in the United Kingdom

Waters
RIGHT ON TIME.

